Marcaine 0,25 % Adrénaline (Epinephrine, Bupivacaine Hydrochloride, Anhydrous)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing the initiation and conduction of nerve impulses. This inhibition stops pain signals from reaching the brain. The added epinephrine causes vasoconstriction, reducing local blood flow and extending the duration of the anesthetic effect.

The appropriate dose of Marcaine 0,25 % Adrénaline is determined by the prescribing clinician based on the type of procedure, patient weight, and clinical judgment. Dosing guidelines are provided in the product labeling and must be followed by qualified healthcare professionals.

Safety data for Marcaine 0,25 % Adrénaline in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under the guidance of a qualified obstetrician or pediatrician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain if needed) and assists with import documentation.

Compared with shorter‑acting agents such as lidocaine, bupivacaine provides a longer duration of anesthesia, often lasting several hours. The addition of epinephrine further extends this period by reducing systemic absorption. However, bupivacaine has a higher potential for cardiotoxicity, so careful dosing and monitoring are essential.

Store the solution at room temperature, below 25 °C, in its original packaging. Protect it from direct sunlight, moisture, and extreme temperatures. Do not freeze. Inspect the vial for particulate matter or discoloration before use, and discard any product that appears compromised.

Marcaine 0,25 % Adrénaline is administered by a qualified healthcare professional via injection. Common routes include epidural injection for labor analgesia and infiltration for surgical field anesthesia. The product is supplied as a sterile solution for single‑use vials and must be injected using aseptic technique.

Serious risks include cardiovascular collapse, severe arrhythmias, central nervous system toxicity such as seizures, and anaphylactic reactions. These events are rare but require immediate medical intervention. Continuous monitoring of vital signs during and after administration is recommended to detect early signs of toxicity.

Contraindications include patients with known hypersensitivity to bupivacaine, epinephrine, or any component of the formulation. It should also be avoided in individuals with severe cardiac disease, uncontrolled hypertension, or certain arrhythmias, as epinephrine may exacerbate these conditions. Clinical judgment is required for each patient.